{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:25:39Z","timestamp":1792268739606,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s10384-014-0310-z","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T01:04:56Z","timestamp":1393290296000},"page":"237-243","source":"Crossref","is-referenced-by-count":21,"title":["Intravitreal injection of bevacizumab for retinopathy of prematurity"],"prefix":"10.1007","volume":"58","author":[{"given":"Kazuki","family":"Kuniyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sakuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"310_CR1","first-page":"419","volume":"22","author":"M Nagata","year":"1968","unstructured":"Nagata M, Kobayashi Y, Fukuda H, Suekane K. Photocoagulation for the treatment of the retinopathy of prematurity. Rinsho Ganka (Jpn). 1968;22:419\u201326.","journal-title":"Rinsho Ganka (Jpn)"},{"key":"310_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471\u20139.","journal-title":"Arch Ophthalmol"},{"key":"310_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol. 2003;121:1684\u201396.","journal-title":"Arch Ophthalmol"},{"key":"310_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1091-8531(97)90008-2","volume":"1","author":"TL Young","year":"1997","unstructured":"Young TL, Anthony DC, Pierce E, Foley E, Smith LEH. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS. 1997;1:105\u201310.","journal-title":"J AAPOS"},{"key":"310_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","volume":"87","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87:77\u201388.","journal-title":"Mayo Clin Proc"},{"key":"310_CR6","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin\u00ae) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"suppl","key":"310_CR7","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","volume":"28","author":"H Quiroz-Mercado","year":"2008","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RVP. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28(suppl):S19\u201325.","journal-title":"Retina"},{"issue":"suppl","key":"310_CR8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28(suppl):S13\u20138.","journal-title":"Retina"},{"key":"310_CR9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Grasefes Arch Clin Exp Ophthalmol. 2010;248:1257\u201362.","journal-title":"Grasefes Arch Clin Exp Ophthalmol"},{"key":"310_CR10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","volume":"31","author":"R Axer-Siegel","year":"2011","unstructured":"Axer-Siegel R, Snir M, Ron Y, Friling R, Sirota L, Weinberger D. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Retina. 2011;31:1239\u201347.","journal-title":"Retina"},{"key":"310_CR11","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3109\/14767058.2012.684109","volume":"25","author":"C Dani","year":"2012","unstructured":"Dani C, Frosini S, Fortunato P, Bertini G, Pratesi S, Pollazzi L, et al. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series. J Matern Fetal Neonatal Med. 2012;25:2194\u20137.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"310_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10384-012-0141-8","volume":"56","author":"HJ Sun","year":"2012","unstructured":"Sun HJ, Choi KS, Lee SJ. Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report. Jpn J Ophthalmol. 2012;56:476\u201380.","journal-title":"Jpn J Ophthalmol"},{"key":"310_CR13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Mart\u00ednez-Castellanos","year":"2013","unstructured":"Mart\u00ednez-Castellanos MA, Schwartz S, Hern\u00e1ndez-Rojas ML, Kon-Jara VA, Grac\u00eda-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5\u00a0years of follow-up. Retina. 2013;33:329\u201338.","journal-title":"Retina"},{"key":"310_CR14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450\u20135.","journal-title":"Br J Ophthalmol"},{"key":"310_CR15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/IAE.0b013e3181a3b848","volume":"29","author":"NI Nonobe","year":"2009","unstructured":"Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina. 2009;29:579\u201385.","journal-title":"Retina"},{"key":"310_CR16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315.","journal-title":"N Engl J Med"},{"key":"310_CR17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831\u20138.","journal-title":"Retina"},{"key":"310_CR18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118:176\u201383.","journal-title":"Ophthalmology"},{"key":"310_CR19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5301\/ejo.5000176","volume":"22","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol. 2012;22:685\u20136.","journal-title":"Eur J Ophthalmol"},{"key":"310_CR20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155:150\u20138.","journal-title":"Am J Ophthalmol"},{"key":"310_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","volume":"14","author":"SY Jang","year":"2010","unstructured":"Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS. 2010;14:457\u20139.","journal-title":"J AAPOS"},{"key":"310_CR22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","volume":"26","author":"BJ Lee","year":"2012","unstructured":"Lee BJ, Kim JH, Yu YS. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye. 2012;26:903\u201310.","journal-title":"Eye"},{"key":"310_CR23","first-page":"801","volume":"130","author":"RD Patel","year":"2012","unstructured":"Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130:801\u20132.","journal-title":"Arch Ophthalmol"},{"key":"310_CR24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"310_CR25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013;17:323\u20135.","journal-title":"J AAPOS"},{"key":"310_CR26","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","volume":"54","author":"M McCloskey","year":"2013","unstructured":"McCloskey M, Wang H, Jiang Y, Smith GW, Strange J, Hartnett ME. Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013;54:2020\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"310_CR27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","volume":"131","author":"C Karaca","year":"2013","unstructured":"Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131:1099\u2013101.","journal-title":"JAMA Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-014-0310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-014-0310-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-014-0310-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:20:39Z","timestamp":1559146839000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-014-0310-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s10384-014-0310-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}